



Boryung pharmaceuticals Co., Ltd.

CEO
Jae-hyun Ahn, Sam-soo Lee

Location
136, Changgyeonggung-ro,
Chongro-ku, Seoul

Specialty
1. Hypertension NCE
2. Oncology NCE
3. Cardiovascular disease IMD

Tel / Fax / E-mail
T. 82-2-708-8000
F. 82-31-491-5340

Boryung Pharmaceutical strives to be a company which will continue to practice 'contributing to the health of mankind' by preparing for the future and taking on challenges with innovation. We have made every effort to free everyone from the pains of disease. As a result, the people of Korea have come to love our products.

We has developed Kanarb, the No. 1 ARB in Korea, and kanarb combination drugs by our proprietary technology. We has successfully licensed out Kanarb Family to 38 countries.

Main Products

Product (Ingredient)	Use	Exporting Countries	Remarks
Kanarb (Fimasartan)	Hypertension	13 Latin countries, Russia, China, 13 Southeast Asian countries, 10 African countries	Launched
Dukarb (Fimasartan+Amlodipine)	Hypertension	25 Latin countries, 13 Southeast Asian countries, 10 African countries	Launched
Tuvero (Fimasartan+Rosuvastatin)	Essential hypertension and dyslipidemia	25 Latin countries, 13 Southeast Asian countries	Launched
Kanarb plus (Fimasartan+HTCZ)	Hypertension	13 Latin countries, 13 Southeast Asian countries, 8 African countries	Launched
Dukaro (Fimasartan+Amlodipine+Rosuvastatin)	Hypertension and dyslipidemia		Launched
Gelfos M (Colloidal Aluminum Phosphate, Magnesium hydroxide, Simethicone)	Gastric antacid	China, Taiwan	Launched
Besto (Lafutidine)	Gastric ulcer		Launched

R&D Pipeline

		Indication	Discovery	Preclinical	Phase I	Phase II	Phase III	Launch
NCE	BR2002	Lymphoma						
	BR2006	Cancer						
	BR2007	Cancer						
IMD	BR1006	Hypertension Dyslipidemia						
	BR1007	CKD						
	BR1008	Hypertension Dyslipidemia						
	BR1009	Hypertension Diabetes						
	BR1010	Hypertension						
	BR4002	Alzheimer's disease						